StreetInsider.com News Articles

Form 8-K MIMEDX GROUP, INC. For: Oct 15

Fri, 16 Oct 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20261016/27196211.html

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

Wed, 14 Oct 2026 16:01:00 -0400

MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

The conference call can be accessed using the following information:

Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13762954

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

Wed, 14 Oct 2026 16:01:00 -0400

The conference call can be accessed using the following information:

Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13762954

MiMedx wins federal court ruling on Axiofill FDA classification

Wed, 23 Sep 2026 16:01:24 -0400

MiMedx Group, Inc. (Nasdaq: MDXG) announced that the U.S. District Court for the Northern District of Georgia vacated two FDA determinations regarding the regulatory classification of its AXIOFILL product, a human placental-derived extracellular matrix particulate.

The court vacated FDA's finding that AXIOFILL is not a Section 361 HCT/P on the grounds that it is more than minimally manipulated, and also vacated FDA's classification of AXIOFILL as a biological product rather than a medical device. Both matters were remanded to FDA for further consideration consistent with the court's order.

The court found that FDA had incorrectly interpreted its minimal-manipulation regulation by focusing on

MiMedx wins federal court ruling on Axiofill FDA classification

Wed, 23 Sep 2026 16:01:24 -0400

The court found that FDA had incorrectly interpreted its minimal-manipulation regulation by focusing on

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Wed, 23 Sep 2026 16:01:00 -0400

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product

Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient

MARIETTA, Ga., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation challenging the U.S. Food and Drug Administration’s (“FDA”) regulatory classification of AXIOFILL, the Company’s human placental-derived extracellular matrix particulate

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Wed, 23 Sep 2026 16:01:00 -0400

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product

Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient

Cantor Fitzgerald Reiterates Overweight Rating on MiMedx Group (MDXG)

Tue, 15 Sep 2026 09:32:11 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $8.00 price target on MiMedx Group (NASDAQ: MDXG).

The analyst commented, "The Sanara (SMTI, NC) acquisition remains the focal point, with the shareholder vote set for 9/30 (barring FTC issues) and a close possible by YE26; management sees the deal as accretive and a rare instance of an entire business rolling over cleanly into the combined entity. It begs the question if a rerating here is possible, as wound care stabilizes and investors see the company can integrate Sanara while still generating cash ‒ our stance is yes. Strategically, the deal

MIMEDX to Participate in Upcoming Investor Conferences

Tue, 08 Sep 2026 08:00:00 -0400

MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

Cantor Global Healthcare Conference | New York, NY
Wednesday, September 9, 2026
1:1 sessions

Lake Street BIG10 Best Ideas Growth Conference | New York, NY
Thursday, September 10, 2026
1:1 sessions

Investors interested in meeting with senior management at these events may contact their respective Cantor or Lake Street representative.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans

MIMEDX to Participate in Upcoming Investor Conferences

Tue, 08 Sep 2026 08:00:00 -0400

Cantor Global Healthcare Conference | New York, NY
Wednesday, September 9, 2026
1:1 sessions

Lake Street BIG10 Best Ideas Growth Conference | New York, NY
Thursday, September 10, 2026
1:1 sessions

Investors interested in meeting with senior management at these events may contact their respective Cantor or Lake Street representative.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans

MiMedx Group (MDXG) PT Raised to $8 at Craig-Hallum

Thu, 27 Aug 2026 09:16:08 -0400

Craig-Hallum analyst Chase Knickerbocker raised the price target on MiMedx Group (NASDAQ: MDXG) to $8.00 (from $6.00) while maintaining a Buy rating.

Form S-4 MIMEDX GROUP, INC.

Tue, 25 Aug 2026 06:01:00 -0400

http://archive.fast-edgar.com/20260825/AA2ZI22CLZ22G29222ZM2CY2SLNPZ222Y68Q

Filed on: August 25, 2026

Form S-4 MIMEDX GROUP, INC.

Tue, 25 Aug 2026 06:01:00 -0400

http://archive.fast-edgar.com/20260825/AA2ZI22CLZ22G29222ZM2CY2SLNPZ222Y68Q

Filed on: August 25, 2026

MiMedx Group (MDXG) Reiterated at Overweight by Cantor Fitzgerald: Wound Care Market Stable

Mon, 17 Aug 2026 08:00:02 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $8.00 price target on MiMedx Group (NASDAQ: MDXG).

The analyst commented, "We are encouraged by the early signs of stabilization in the Wound Care market & synergistic acquisition in Surgical Care. 2Q26 updates around Wound Care support our thesis, driven by our payor coverage, that the market can recover from reimbursement pressures. MDXG believes it is seeing early signs of stabilization as volumes increased 22% Q/Q & 44% Q/ Q in centers where MDXG has concentrated its efforts. The proposed 2027 physician fee schedule failed to correct these pressures, but MDXG

Form 8-K/A MIMEDX GROUP, INC. For: Jul 29

Tue, 11 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260811/26906643.html

Form 8-K/A MIMEDX GROUP, INC. For: Jul 29

Tue, 11 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260811/26906643.html

H.C. Wainwright Downgrades Sanara MedTech (SMTI) to Neutral

Thu, 30 Jul 2026 06:39:13 -0400

(Updated - July 30, 2026 6:39 AM EDT)

H.C. Wainwright analyst Yi Chen downgraded Sanara MedTech (NASDAQ: SMTI) from Buy to Neutral.

The analyst comments "MiMedx to acquire Sanara at $350M enterprise value in a cash and stock transaction. Yesterday, MiMedx Group (MDXG; not rated) and Sanara MedTech announced that they have entered into a definitive merger agreement under which MiMedx will acquire all the outstanding shares of Sanara in a cash and stock transaction valued at $35 ($33 in cash and 0.4735 share of MDXG common stock) per Sanara share with a total enterprise value of approximately $350M. According to management,

H.C. Wainwright Downgrades Sanara MedTech (SMTI) to Neutral

Thu, 30 Jul 2026 06:39:13 -0400

(Updated - July 30, 2026 6:39 AM EDT)

H.C. Wainwright analyst Yi Chen downgraded Sanara MedTech (NASDAQ: SMTI) from Buy to Neutral.

H.C. Wainwright Downgrades Sanara MedTech (SMTI) to Neutral

Thu, 30 Jul 2026 06:39:13 -0400

(Updated - July 30, 2026 6:39 AM EDT)

H.C. Wainwright analyst Yi Chen downgraded Sanara MedTech (NASDAQ: SMTI) from Buy to Neutral.

H.C. Wainwright Downgrades Sanara MedTech (SMTI) to Neutral

Thu, 30 Jul 2026 06:39:13 -0400

(Updated - July 30, 2026 6:39 AM EDT)

H.C. Wainwright analyst Yi Chen downgraded Sanara MedTech (NASDAQ: SMTI) from Buy to Neutral.

MiMedx Group (MDXG) Misses Q2 EPS by 3c

Wed, 29 Jul 2026 16:57:56 -0400

MiMedx Group (NASDAQ: MDXG) reported Q2 EPS of ($0.05), $0.03 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $64 million versus the consensus estimate of $63.45 million.

For earnings history and earnings-related data on MiMedx Group (MDXG) click here.

Form 8-K MIMEDX GROUP, INC. For: Jul 29

Wed, 29 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260729/26835013.html

Form 8-K MIMEDX GROUP, INC. For: Jul 29

Wed, 29 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260729/26835013.html

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

Wed, 29 Jul 2026 16:07:00 -0400

Reports Second Quarter Net Sales of $64 Million

Reiterates Full Year Financial Outlook on a Standalone Basis

Announces Plans to Acquire Sanara MedTech

Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET

MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2026.

Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "During the second quarter, we delivered another strong performance in our Surgical franchise, with 15% year-over-year revenue growth balanced

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

Wed, 29 Jul 2026 16:07:00 -0400

Reports Second Quarter Net Sales of $64 Million

Reiterates Full Year Financial Outlook on a Standalone Basis

Announces Plans to Acquire Sanara MedTech

Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET

MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2026.